<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005389.pub2" GROUP_ID="NEONATAL" ID="961404061318553823" MERGED_FROM="" MODIFIED="2017-02-07 16:58:00 +0000" MODIFIED_BY="Colleen Ovelman" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;/p&gt;&lt;p&gt;Old title: Fluid restriction for treatment of chronic lung disease&lt;/p&gt;&lt;p&gt;CL 3/05 protocol&lt;/p&gt;" NOTES_MODIFIED="2017-02-07 11:57:05 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2017-02-07 11:56:01 -0500" MODIFIED_BY="Colleen Ovelman">
<TITLE MODIFIED="2016-03-25 10:35:16 -0400" MODIFIED_BY="Colleen Ovelman">Fluid restriction for treatment of preterm infants with chronic lung disease</TITLE>
<CONTACT>
<PERSON ID="15171" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Keith</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Barrington</LAST_NAME>
<SUFFIX/>
<POSITION>Chief, Division of Neonatology</POSITION>
<EMAIL_1>keith.barrington@umontreal.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>CHU Ste-Justine</ORGANISATION>
<ADDRESS_1>3175 Cote Ste Catherine</ADDRESS_1>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP>H3T 1C5</ZIP>
<REGION>QC</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>514 345 4931 ext. 5929</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-02-07 11:56:01 -0500" MODIFIED_BY="Colleen Ovelman">
<PERSON ID="15171" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Keith</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Barrington</LAST_NAME>
<SUFFIX/>
<POSITION>Chief, Division of Neonatology</POSITION>
<EMAIL_1>keith.barrington@umontreal.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>CHU Ste-Justine</ORGANISATION>
<ADDRESS_1>3175 Cote Ste Catherine</ADDRESS_1>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP>H3T 1C5</ZIP>
<REGION>QC</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>514 345 4931 ext. 5929</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="70050831384199387045111208163000" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Etienne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fortin-Pellerin</LAST_NAME>
<SUFFIX/>
<POSITION>Neonatal Fellow</POSITION>
<EMAIL_1>etienne.fortin-pellerin@usherbrooke.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neonatology</DEPARTMENT>
<ORGANISATION>Sainte Justine University Health Center</ORGANISATION>
<ADDRESS_1>3175 Cote Sainte Catherine</ADDRESS_1>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP>H3T 1C5</ZIP>
<REGION>QC</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 514 345 4931</PHONE_1>
<PHONE_2/>
<FAX_1>+1 514 345 7725</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1505261444013977529812598646318" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Thomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pennaforte</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>thomas.pennaforte@umontreal.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Université de Montréal</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP/>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-03-09 12:28:44 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="16" MONTH="2" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="2" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="2" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2017"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-18 17:06:49 -0400" MODIFIED_BY="Colleen Ovelman"/>
<HISTORY MODIFIED="2016-03-24 10:36:36 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-03-24 10:36:36 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-10-03 23:24:54 -0400" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-10-03 23:24:54 -0400" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-10-03 23:24:54 -0400" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201600005C</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-02-07 11:57:05 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-01-24 08:27:31 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2017-01-24 08:12:27 -0500" MODIFIED_BY="[Empty name]">Fluid restriction as a treatment for preterm infants developing chronic lung disease</TITLE>
<SUMMARY_BODY MODIFIED="2017-01-24 08:27:31 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
<BR/>Babies born prematurely are at risk of developing a form of chronic lung disease which is defined as persistent need for oxygen once the child has reached a corrected gestational age of 36 weeks. As fluid accumulation in the lung is one of the processes involved in the early phases of lung disease in premature babies, low fluid intake might halt the progression of the insult and result in lower rates of chronic lung disease of prematurity.</P>
<P>
<B>Study characteristics</B>
<BR/>Our search identified only one study comparing two volumes of fluid intake in preterm infants with early signs of chronic lung disease. Unfortunately, this study did not report progression to established chronic lung disease. Hence, no infant could be included in this analysis.</P>
<P>Other outcomes, including days that the baby needed extra oxygen, proportion of infants discharged from hospital on oxygen, days of assisted ventilation, duration of hospital stay, weight gain and serious apnoeas were not affected by the volume of fluid received (from the evidence graded as low quality). The evidence is current to February 2016.</P>
<P>
<B>Key results</B>
<BR/>There is no study comparing low to high fluid intake in a population of preterm babies with early signs of chronic respiratory disease to prevent progression to full blown chronic lung disease or death. Other outcomes were not improved by fluid restriction.</P>
<P>
<B>Quality of evidence</B>
<BR/>Not applicable.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-01-24 09:21:35 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-02-29 10:46:32 -0500" MODIFIED_BY="[Empty name]">
<P>Fluid restriction is often recommended as part of the management of infants with early or established bronchopulmonary dysplasia (BPD).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-01-24 09:21:35 -0500" MODIFIED_BY="[Empty name]">
<P>To determine whether fluid restriction as part of the therapeutic intervention for early or established BPD improves clinical outcomes.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-01-24 08:08:30 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1) in the Cochrane Library (searched 16 February 2016), MEDLINE via PubMed (1966 to 16 February 2016), Embase (1980 to 16 February 2016), and CINAHL (1982 to 16 February 2016). We also searched clinical trials' databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-10-04 09:17:45 -0400" MODIFIED_BY="[Empty name]">
<P>Prospective randomised clinical trials comparing two distinct fluid administration volumes in preterm infants with early or established BPD.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-01-24 08:09:31 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of Cochrane Neonatal. For the included trial, we extracted data and assessed the risk of bias, and used GRADE methods to assess the quality of the evidence. The outcomes considered in this review are effects on mortality or requirement for oxygen at 36 weeks' postmenstrual age (primary outcome measure), the duration of supplemental oxygen therapy, proportion of infants discharged from hospital on oxygen, duration of assisted ventilation, duration of hospitalisation, weight gain, feeding tolerance, apnoea, necrotizing enterocolitis, renal dysfunction or nephrocalcinosis, lung mechanics, and use of diuretic therapy (secondary outcome measures).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-01-06 12:04:24 -0500" MODIFIED_BY="[Empty name]">
<P>One trial was found, including 60 preterm infants at 28 days of age with persistent oxygen requirements. Infants were randomised to either 180 mL/kg/day of standard formula or 145 mL/kg/day of concentrated formula. This single study did not provide data regarding our primary outcome. No effects of the intervention were found on any of our secondary outcomes. The quality of the evidence from this study was graded low.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-02-29 10:46:48 -0500" MODIFIED_BY="[Empty name]">
<P>There is no evidence to support the practice of fluid restriction in infants with early or established BPD.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-02-07 11:57:05 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2017-02-07 11:57:05 -0500" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2017-01-24 08:52:57 -0500" MODIFIED_BY="[Empty name]">
<P>Bronchopulmonary dysplasia (BPD), often referred to as chronic lung disease (CLD) of prematurity, is a frequent complication of neonatal intensive care. It occurs more frequently in the very immature infant and leads to persistent respiratory distress and a long-term oxygen requirement. An inflammatory interstitial pulmonary oedema was described as part of the pathogenesis of early CLD in the preterm infant (<LINK REF="REF-Northway-1967" TYPE="REFERENCE">Northway 1967</LINK>; <LINK REF="REF-Brown-1978" TYPE="REFERENCE">Brown 1978</LINK>). It is not known if this is still the case in more recently treated infants in whom a reduction in alveolar development seems to be paramount in the development of "the new BPD" (<LINK REF="REF-Jobe-2011" TYPE="REFERENCE">Jobe 2011</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-01-24 08:56:48 -0500" MODIFIED_BY="[Empty name]">
<P>Because of the presence of excess lung water, diuretics have been investigated as a therapeutic option. They are now used frequently in the treatment of preterm infants with BPD. Physiological studies of diuretics have demonstrated short-term effects on lung mechanics but no long-term clinical benefits have been proven (<LINK REF="REF-Kao-1983" TYPE="REFERENCE">Kao 1983</LINK>; <LINK REF="REF-McCann-1985" TYPE="REFERENCE">McCann 1985</LINK>).</P>
<P>Possibly by extrapolation from the use of diuretics came the practice of restricting fluid intake as a treatment for preterm infants with CLD. Some neonatal textbooks recommend restricting fluid as a treatment for BPD (<LINK REF="REF-Niermeyer-1988" TYPE="REFERENCE">Niermeyer 1988</LINK>; <LINK REF="REF-Bancalari-2002" TYPE="REFERENCE">Bancalari 2002</LINK>). By the time fluid restriction is contemplated, most infants are receiving enteral nutrition, either totally or at least partially.</P>
<P>Fluid restriction requires limiting total (enteral and parenteral) fluid intake to less than the amount usually recommended (i.e. to less than 150 mL/kg/day), with the goal of improving pulmonary function.</P>
</INTERVENTION>
<THEORY MODIFIED="2017-01-24 08:57:08 -0500" MODIFIED_BY="[Empty name]">
<P>Fluid restriction is used in the hope that it will reduce pulmonary oedema and thus improve pulmonary function, and perhaps lessen lung injury.</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-02-07 11:57:05 -0500" MODIFIED_BY="[Empty name]">
<P>There are concerns with the practice of fluid restriction as it may interfere with the delivery of adequate nutrition. It seems likely that restricting fluid intake will lead to a decrease in urine output; within clinically acceptable limits of fluid intake it is questionable whether fluid restriction will lead to changes in total body water, lung fluid balance or pulmonary function. In addition, the reduction of free water intake will probably lead to an increase in renal solute load and potentially to a greater incidence of renal dysfunction and nephrocalcinosis. On the other hand, larger fluid volumes could be associated with an increase in feeding intolerance or with a risk of necrotizing enterocolitis (<LINK REF="REF-Viswanathan-2015" TYPE="REFERENCE">Viswanathan 2015</LINK>).</P>
<P>Randomised comparisons of differing levels of fluid intake in early life of the preterm infant as a means of preventing BPD have been performed and systematically reviewed (<LINK REF="REF-Bell-1998" TYPE="REFERENCE">Bell 1998</LINK>). These studies showed that reduced fluid intakes led to a non-significant trend toward reduction in the risk of BPD and a significant reduction in death (<LINK REF="REF-Bell-1998" TYPE="REFERENCE">Bell 1998</LINK>).</P>
<P>Once BPD has developed or is developing, fluid restriction as part of treatment of the disease is sometimes considered by physicians, and continues to be recommended as a part of treatment. Review articles recommending fluid restriction usually provide no references, or refer solely to other review articles.</P>
<P>We wished to determine if there is adequate evidence to support this practice. Recommended fluid intake can be defined as 150 ml/kg/day or more (<LINK REF="REF-Gregory-2005" TYPE="REFERENCE">Gregory 2005</LINK>); we therefore considered a fluid intake less than 150 ml/kg/day as 'restricted'. For the purpose of this review, we defined BPD as oxygen requirement at 28 postnatal days, and CLD as oxygen requirement at 36 weeks' postmenstrual age.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-02-06 13:00:12 -0500" MODIFIED_BY="[Empty name]">
<P>To determine whether fluid restriction as part of the therapeutic intervention for early or established BPD improves clinical outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-02-06 13:02:54 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-01-24 10:20:05 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2017-01-24 09:28:27 -0500" MODIFIED_BY="[Empty name]">
<P>Prospective randomised and quasi-randomised trials. We excluded short-term cross-over studies as not being informative for our primary outcome measure.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-01-24 09:30:00 -0500" MODIFIED_BY="[Empty name]">
<P>Preterm infants (&lt; 34 weeks) with early or established BPD. Established BPD was defined as oxygen need and evidence of respiratory insufficiency at 28 days of age. Early BPD was defined as a persistent oxygen need, respiratory insufficiency and high predicted likelihood of development of established BPD after a minimum of 21 days of age. Maximum age of enrolment into the study was 36 weeks' postmenstrual age.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-01-24 09:31:01 -0500" MODIFIED_BY="[Empty name]">
<P>We searched for studies comparing two different levels of fluid intake. Because there is a wide range of possible fluid intakes in such infants, in order to group the studies we assumed that normal fluid intake is 140 to 150 ml/kg/day, and we intended to group the subjects into unrestricted (&#8805; 150 ml/kg/day) and fluid restricted (&lt; 150 ml/kg/day).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-01-24 10:20:05 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-01-24 09:31:09 -0500" MODIFIED_BY="[Empty name]">
<P>Mortality or requirement for oxygen at 36 weeks' postmenstrual age (CLD).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-01-24 10:20:05 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Duration of supplemental oxygen in days from enrolment until discharge.</LI>
<LI>Proportion of infants discharged from hospital on oxygen.</LI>
<LI>Duration of assisted ventilation in days from enrolment until discharge.</LI>
<LI>Duration of hospitalisation in days from enrolment until discharge.</LI>
<LI>Daily weight gain from enrolment until the end of the intervention.</LI>
<LI>Apnoea: number (proportion) of infants with problematic apnoea.</LI>
<LI>Feeding intolerance: number (proportion) of infants with feeding intolerance requiring alteration in feeds.</LI>
<LI>Necrotizing enterocolitis (NEC): number (proportion) of infants with NEC defined as Bell stage two or more.</LI>
<LI>Renal dysfunction: mean changes in serum creatinine between enrolment and the end of the intervention.</LI>
<LI>Nephrocalcinosis: proportion of infants with nephrocalcinosis on renal ultrasound or CT scan.</LI>
<LI>Lung mechanics: percentage change in dynamic compliance between enrolment and the end of the intervention.</LI>
<LI>Need for diuretics: number of doses of diuretic (loop diuretic or thiazide) needed per participant since the start of intervention.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-01-24 09:38:25 -0500" MODIFIED_BY="[Empty name]">
<P>We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see <A HREF="http://neonatal.cochrane.org/resources-review-authors">the Cochrane Neonatal search strategy for specialized register</A>).<BR/>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2017-01-24 09:38:25 -0500" MODIFIED_BY="[Empty name]">
<P>We conducted a comprehensive search including: Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1) in the Cochrane Library (searched 16 February 2016); MEDLINE via PubMed (1966 to 16 February 2016); Embase (1980 to 16 February 2016); and CINAHL (1982 to 16 February 2016) using the following search terms: (fluid OR food, formulated) AND (bronchopulmonary dysplasia OR BPD OR chronic lung disease OR CLD), plus database-specific limiters for RCTs and neonates (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the full search strategies for each database). We did not apply language restrictions.<BR/>
<BR/>We searched clinical trials' registries for ongoing or recently completed trials (<A HREF="http://clinicaltrials.gov">ClinicalTrials.gov</A>; the World Health Organization&#8217;s International Clinical Trials Registry Platform <A HREF="http://www.who.int/ictrp/search/en/">www.who.int/ictrp/search/en/</A>; and <A HREF="http://www.isrctn.com/">the ISRCTN Registry</A>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-03-23 20:45:09 -0400" MODIFIED_BY="[Empty name]">
<P>We examined the references in all studies identified as potentially relevant.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-02-06 13:02:54 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of Cochrane and Cochrane Neonatal (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Review authors independently assessed trials for inclusion and methodological quality. Differences were resolved by discussion. We planned to contact study authors if we needed additional information.<BR/>
</P>
<STUDY_SELECTION MODIFIED="2016-03-24 06:26:59 -0400" MODIFIED_BY="[Empty name]">
<P>All three review authors screened the title and abstract of all studies identified by the above search strategy. We assessed the full text of any potentially eligible reports and excluded those studies that did not meet all of the inclusion criteria. We discussed any disagreements until consensus was achieved.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-02-06 13:02:17 -0500" MODIFIED_BY="[Empty name]">
<P>All three review authors extracted the data separately. Any disagreements were discussed until consensus was achieved. We contacted trial authors for further information if data from the trial reports was insufficient.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-02-06 13:02:54 -0500" MODIFIED_BY="[Empty name]">
<P>We used the criteria and standard methods of <A HREF="http://neonatal.cochrane.org/resources-review-authors">Cochrane Neonatal</A>. The methodological quality of the studies was assessed using the following key criteria: allocation concealment (blinding of randomisation), blinding of intervention, completeness of follow-up, and blinding of outcome measurement/assessment. For each criterion, assessment was 'yes', 'no' or 'unclear'. Additional information from the trial authors was requested to clarify methodology and results as necessary. This information was included in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.</P>
<P>In addition, the review authors independently assessed the risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>The methodological quality of the studies was assessed using the following criteria.</P>
<OL>
<LI>Sequence generation (evaluating possible selection bias). For each included study, we described the method used to generate the allocation sequence as: adequate (any truly random process e.g. random number table; computer random number generator); inadequate (any non-random process e.g. odd or even date of birth; hospital or clinic record number); or unclear.</LI>
<LI>Allocation concealment (evaluating possible selection bias). For each included study, we described the method used to conceal the allocation sequence as: adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); inadequate (open random allocation; unsealed or non-opaque envelopes; alternation; date of birth); or unclear.</LI>
<LI>Blinding (evaluating possible performance bias). For each included study, we described the methods used to blind study participants and personnel from knowledge of which intervention a participant received. Blinding was assessed separately for different outcomes or classes of outcomes. We assessed the methods as: adequate, inadequate, or unclear for participants; adequate, inadequate, or unclear for study personnel; and adequate, inadequate, or unclear for outcome assessors.</LI>
<LI>Incomplete outcome data (evaluating possible attrition bias through withdrawals, dropouts, protocol deviations). For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. We assessed methods as: adequate (&lt; 20% missing data); inadequate (&gt; 20% missing data); or unclear;</LI>
<LI>Selective reporting bias. For each included study where the protocol is available (through trials' registers), we described how we investigated the possibility of selective outcome reporting bias and what we found. We assessed the methods as: adequate (where it was clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review had been reported); inadequate (where not all the study's prespecified outcomes had been reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported); or unclear.</LI>
<LI>Other sources of bias. We noted other possible sources of bias (for example, whether there was a potential source of bias related to the specific study design or whether the trial was stopped early owing to some data-dependent process). We assessed whether each study was free of other problems that could put it at risk of bias as: yes; no; or unclear.</LI>
<LI>Funding sources: when reported we divided funding sources into funding from local funds (hospital, research centre, or university), charitable foundations, government agencies, or from industry. If funding was from industry, and industry also had substantial input into study design or conduct or analysis, then that was determined to be a high risk of bias. Funding from sources that had no potential financial benefit from the results was considered to be a low risk of bias. Unclear or partial funding was considered unclear risk of bias.</LI>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-03-24 10:32:25 -0400" MODIFIED_BY="[Empty name]">
<P>We calculated risk ratio (RR) and risk difference (RD) for dichotomous data and mean difference (MD) for continuous data, with respective 95% confidence intervals (CIs). When it was deemed appropriate to combine two or more study arms, we obtained the treatment effects from the combined data using the methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We determined the number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) for a statistically significant difference in the RD.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-10-04 09:18:36 -0400" MODIFIED_BY="[Empty name]">
<P>The only trial included was an individually randomised parallel group trial.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-04-06 15:19:54 -0400" MODIFIED_BY="[Empty name]">
<P>We requested additional data from the trial investigators for data on important outcomes which were missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-01-24 10:13:01 -0500" MODIFIED_BY="[Empty name]">
<P>If more than one trial was included in a meta-analysis, we planned to examine the treatment effects of individual trials and heterogeneity between trial results by inspecting the forest plots. We planned to calculate the I² statistic for each analysis to quantify inconsistency across studies and describe the percentage of variability in effect estimates that may be due to heterogeneity rather than sampling error. The I² statistic was to be analysed as follows: less than 25% = no heterogeneity; 25% to 49% = low heterogeneity; 50% to 74% = moderate heterogeneity; and 75%+ = high heterogeneity. If moderate or high heterogeneity was detected (I² statistic &gt; 50%), we would have explored the possible causes (for example, differences in study design, participants, interventions, or completeness of outcome assessments) in sensitivity analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-12-23 09:16:39 -0500" MODIFIED_BY="[Empty name]">
<P>We planned to investigate publication bias by using funnel plots if at least 10 clinical trials were included in the systematic review (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-01-24 10:14:32 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group. For categorical outcomes, typical estimates for relative risk (RR) and risk difference (RD) were calculated along with their 95% confidence intervals. For significant results, we planned on reporting the number needed to treat for an additional beneficial outcome or number needed to treat for an additional harmful outcome (NNTB/NNTH). A fixed-effect model was assumed. Continuous outcomes were analysed using weighted mean difference, assuming a fixed-effect model.</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality of evidence</HEADING>
<P>We used the GRADE approach, as outlined in the GRADE Handbook (<LINK REF="REF-Sch_x00fc_nemann-2013" TYPE="REFERENCE">Schünemann 2013</LINK>), to assess the quality of evidence for the following (clinically relevant) outcomes: death, chronic lung disease at 36 weeks, duration of invasive and non-invasive assisted ventilation and duration of oxygen therapy.</P>
<P>Two authors independently assessed the quality of the evidence for each of the outcomes above. We considered evidence from randomised controlled trials as high quality but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and presence of publication bias. We used the <LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK> Guideline Development Tool to create a &#8216;Summary of findings&#8217; table to report the quality of the evidence.</P>
<P>The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades:</P>
<OL>
<LI>High: We are very confident that the true effect lies close to that of the estimate of the effect.</LI>
<LI>Moderate: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.</LI>
<LI>Low: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.</LI>
<LI>Very low: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.</LI>
</OL>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-01-24 10:21:45 -0500" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis for the severity of the disease, the different levels of fluid restriction and the duration of the intervention were planned but could not be performed as only one study was found and data for these subgroups was unavailable.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-01-24 10:21:57 -0500" MODIFIED_BY="[Empty name]">
<P>Sensitivity analysis was planned to eliminate trials considered of low quality, but only one trial was found.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-01-24 11:14:36 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-01-24 10:40:46 -0500" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2017-01-24 10:22:56 -0500" MODIFIED_BY="[Empty name]">
<P>The initial search as described found 221 articles, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>
.
</P>
<P>Twenty-five of the articles were reports of randomised controlled trials. Seventeen were randomised comparisons of maternal milk with artificial milk; maternal milk with or without fortification; or of different formulas or fortification of feeds given after discharge from the neonatal intensive care unit.</P>
<P>There were eight reports of trials comparing different fluid intakes in preterm infants in which one outcome reported was either BPD or CLD. Seven of those reports were of RCTs comparing fluid intakes in the first week of life.</P>
<P>There was only one relevant study in which two volumes of fluid intake were compared in infants with early or established BPD.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-01-24 10:40:46 -0500" MODIFIED_BY="[Empty name]">
<P>The only relevant study was <LINK REF="STD-Fewtrell-1997" TYPE="STUDY">Fewtrell 1997</LINK>, a randomised comparison of two different diet/fluid regimes in 60 preterm infants below 1500 grams' birth weight and less than 32 weeks' gestation, who were enrolled as they still required oxygen at 28 days of age. Infants received either standard formula (24 kcal/oz) at 180 mL/kg/day (n = 27) or a high nutrient-density formula (30 kcal/oz) at 145 mL/kg/day (n = 33). The primary outcomes are listed as growth rate; duration and severity of respiratory disease; and energy and protein intake.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-01-06 12:10:38 -0500" MODIFIED_BY="[Empty name]">
<P>The reasons for excluding studies are summarized in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-01-24 10:41:43 -0500" MODIFIED_BY="[Empty name]">
<P>The 'Risk of bias' table revealed a moderate risk of bias in this trial. The intervention was not masked, as it was not feasible to do so; also the research staff performing some of the assessments were not masked. The trial was smaller than originally planned as there were more mothers providing breast milk than expected.</P>
<ALLOCATION MODIFIED="2017-01-06 12:10:51 -0500" MODIFIED_BY="[Empty name]">
<P>Randomisation assignments held in sealed envelopes.</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-01-06 12:10:58 -0500" MODIFIED_BY="[Empty name]">
<P>Unblinded study.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-01-06 12:11:00 -0500" MODIFIED_BY="[Empty name]">
<P>All infants accounted for.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-01-06 12:11:02 -0500" MODIFIED_BY="[Empty name]">
<P>No published or registered protocol was found.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-01-24 10:41:43 -0500" MODIFIED_BY="[Empty name]">
<P>Funded by industry (Ross Laboratories).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-01-24 11:14:36 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Restricted compared with liberal fluid intake (comparison 1)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality or CLD</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Duration of supplemental oxygen in days from enrolment until discharge</HEADING>
<P>All but one infant in each group required oxygen during the study. The median duration of supplemental oxygen was 27.5 days (range 2 to 71) in the high-fluid group, and 28 days (range 2 to 79) in the restricted group. The standard deviations are not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of infants discharged from hospital on oxygen</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of assisted ventilation in days from enrolment until discharge</HEADING>
<P>More of the fluid-restricted infants were on assisted ventilation during the study period, and the median duration of assisted ventilation was longer in the fluid-restricted group (27 days (range 5 to 48) compared to 1 day (range 1 to 16)), but was reported to be not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of hospitalisation</HEADING>
<P>There was no significant effect of restricted compared with liberal fluids on duration of hospitalisation; mean difference three days (95% CI &#8722;7.64 to 13.64). Tests for heterogeneity were not applicable (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Daily weight gain from enrolment until the end of the intervention</HEADING>
<P>There was no significant effect of restricted compared with liberal fluids; mean difference 0.50 g/day (95% CI &#8722;1.22 to 2.22). Tests for heterogeneity were not applicable (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Apnoea: number (proportion) of infants with problematic apnoea</HEADING>
<P>There was no significant effect of restricted compared with liberal fluids; relative risk 1.35, 95% CI 0.98 to 1.86. Risk difference 0.22, 95% CI 0.00 to 0.44. Tests for heterogeneity were not applicable (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Feeding intolerance: number (proportion) of infants with feeding intolerance requiring alteration in feeds</HEADING>
<P>The authors report that there was no significant effect of restricted compared with liberal fluids in the incidence of vomiting, abdominal distension or the volume of gastric aspirate but do not give the figures.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Necrotizing enterocolitis: number (proportion) of infants with NEC defined as Bell stage two or more</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Renal dysfunction: mean changes in serum creatinine between enrolment and the end of the intervention</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nephrocalcinosis: proportion of infants with nephrocalcinosis on renal ultrasound or CT scan</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lung mechanics: percentage change in dynamic compliance between enrolment and the end of the intervention</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Need for diuretics: number of doses of diuretic (loop diuretic or thiazide) needed per participant since the start of intervention</HEADING>
<P>The median number of days of treatment with furosemide were 12 (interquartile range 2 to 41) days in the fluid restricted group versus 31 (interquartile range 6 to 60) days in the liberal fluid group, (P = 0.09).</P>
<P>There were no statistically significant differences between the restricted and liberal fluid regime in any of the primary or secondary outcomes.</P>
<P>The clinically important primary outcomes (death and CLD at 36 weeks) for the 'Summary of findings' tables were either not reported or were reported as median and range. Some data were presented about secondary outcomes that are indirectly related to the primary outcomes, and they are presented in the 'Summary of findings' table.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-01-24 11:25:28 -0500" MODIFIED_BY="[Empty name]">
<P>Despite the frequent recommendation to restrict fluid intake in infants with evolving (early) or established BPD there is no evidence to support the practice. The one available trial did not provide data on the primary outcome and showed no statistically significant effect on the secondary outcomes which were reported. It seems unlikely that modest changes in fluid intake have any effect on pulmonary function. Only a drastic reduction in intake, with a reduction in total body water (i.e. dehydration) might be postulated to potentially have an effect. Adverse effects of fluid restriction may include nutritional inadequacy (avoided in <LINK REF="STD-Fewtrell-1997" TYPE="STUDY">Fewtrell 1997</LINK> by study design) and an increase in effective renal osmotic load, which was not investigated by Fewtrell and colleagues.</P>
<SUMMARY_OF_RESULTS MODIFIED="2016-09-12 14:57:29 -0400" MODIFIED_BY="[Empty name]">
<P>The only applicable trial showed no benefit of restricting fluid intake to preterm infants who still required oxygen at, or after, 28 days of life. But our primary outcome was not reported.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-03-24 06:04:24 -0400" MODIFIED_BY="[Empty name]">
<P>The power of this analysis is low because of the small number of infants studied.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-12-23 09:17:22 -0500" MODIFIED_BY="[Empty name]">
<P>The quality of the evidence from the one trial was low, quality was downgraded for lack of blinding, imprecision of results, and indirectness for our primary outcomes.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-03-24 06:05:01 -0400" MODIFIED_BY="[Empty name]">
<P>We have no financial or other conflicts of interest. </P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-01-24 11:27:13 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-09-12 14:57:41 -0400" MODIFIED_BY="[Empty name]">
<P>Fluid intake in BPD should be adequate to provide sufficient nutrients for growth and lung repair. Calorie requirements of infants with early or established BPD are increased compared to infants with normal lungs. There is no proven advantage of supplying highly concentrated, lower volume feeds. Available evidence is insufficient to either support or refute the use of fluid restriction for BPD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-01-24 11:27:13 -0500" MODIFIED_BY="[Empty name]">
<P>In order to provide a rationale for future RCTs of fluid restriction, physiological studies of short-term fluid restriction (controlled and with adequate masking) are required. if such studies do demonstrate a physiological benefit on lung function or lung fluid content then further RCTs, adequately powered to detect clinically important differences in outcomes, may be justifiable.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST MODIFIED="2017-01-24 11:27:30 -0500" MODIFIED_BY="[Empty name]">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-01-24 11:27:20 -0500" MODIFIED_BY="[Empty name]">
<P>KB designed the protocol and wrote the first draft.</P>
<P>All three authors reviewed the articles found by the literature search.</P>
<P>All three authors edited the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-01-24 11:27:53 -0500" MODIFIED_BY="[Empty name]">
<P>The search strategy was updated to include a search of CINAHL and clinical trial registries.</P>
<P>The methods for the assessment of risk of bias were altered to match current Cochrane standards.</P>
<P>We added the methodology and plan for 'Summary of findings' tables and GRADE recommendations, which were not included in the original protocol.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-02-07 16:58:00 +0000" MODIFIED_BY="Colleen Ovelman">
<STUDIES MODIFIED="2016-03-28 15:16:00 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-03-28 15:16:00 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Fewtrell-1997" MODIFIED="2016-03-28 15:16:00 -0400" MODIFIED_BY="[Empty name]" NAME="Fewtrell 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-03-28 15:16:00 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fewtrell MS, Adams C, Wilson DC, Cairns P, Mcclure G, Lucas A</AU>
<TI>Randomized trial of high nutrient density formula versus standard formula in chronic lung disease</TI>
<SO>Acta Paediatrica.</SO>
<YR>1997</YR>
<VL>86</VL>
<NO>6</NO>
<PG>577-82</PG>
<IDENTIFIERS MODIFIED="2016-03-28 15:16:00 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5083495"/><IDENTIFIER MODIFIED="2016-03-28 15:16:00 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9202790"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5083494"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-01-24 11:43:14 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-01-24 11:43:14 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bancalari-2002" MODIFIED="2017-01-22 13:45:44 -0500" MODIFIED_BY="[Empty name]" NAME="Bancalari 2002" TYPE="BOOK_SECTION">
<AU>Bancalari E</AU>
<TI>Neonatal chronic lung disease</TI>
<SO>Neonatal-Perinatal Medicine</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>1057-70</PG>
<EN>7th</EN>
<ED>Fanaroff A, Martin R</ED>
<PB>Mosby Inc</PB>
<CY>St. Louis, Missouri</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bell-1998" MODIFIED="2008-10-22 11:27:43 -0400" MODIFIED_BY="[Empty name]" NAME="Bell 1998" TYPE="COCHRANE_REVIEW">
<AU>Bell EF, Acarregui MJ</AU>
<TI>Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-22 11:27:43 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-10-22 11:27:43 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000503"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-1978" MODIFIED="2016-03-28 15:16:31 -0400" MODIFIED_BY="[Empty name]" NAME="Brown 1978" TYPE="JOURNAL_ARTICLE">
<AU>Brown ER, Stark A, Sosenko I, Lawson EE, Avery ME</AU>
<TI>Bronchopulmonary dysplasia: possible relationship to pulmonary edema</TI>
<SO>Journal of Pediatrics</SO>
<YR>1978</YR>
<VL>92</VL>
<NO>6</NO>
<PG>982-4</PG>
<IDENTIFIERS MODIFIED="2016-03-28 15:16:31 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-28 15:16:31 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="660373"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro" MODIFIED="2016-03-21 10:55:00 -0400" MODIFIED_BY="Colleen Ovelman" NAME="GRADEpro" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<TO>available from www.gradepro.org</TO>
<YR>2014</YR>
<ED>[insert date of use]</ED>
<PB>McMaster University</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gregory-2005" MODIFIED="2017-01-22 13:47:04 -0500" MODIFIED_BY="[Empty name]" NAME="Gregory 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gregory K</AU>
<TI>Update on nutrition for preterm and full-term infants</TI>
<SO>Journal of Obstetric, Gynecologic, and Neonatal Nursing</SO>
<YR>2005</YR>
<VL>34</VL>
<NO>1</NO>
<PG>98-108</PG>
<IDENTIFIERS MODIFIED="2016-03-28 15:16:53 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-28 15:16:53 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15673653"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-01-22 13:48:20 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jobe-2011" MODIFIED="2017-01-22 13:49:32 -0500" MODIFIED_BY="[Empty name]" NAME="Jobe 2011" TYPE="JOURNAL_ARTICLE">
<AU>Jobe AH</AU>
<TI>The New Bronchopulmonary Dysplasia</TI>
<SO>Current Opinion in Pediatrics</SO>
<YR>2011</YR>
<VL>23</VL>
<NO>2</NO>
<PG>167-72</PG>
<IDENTIFIERS MODIFIED="2016-03-28 15:17:27 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-28 15:17:27 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21169836"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kao-1983" MODIFIED="2016-03-28 15:17:45 -0400" MODIFIED_BY="[Empty name]" NAME="Kao 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kao LC, Warburton D, Sargent CW, Platzker AC, Keens TG</AU>
<TI>Furosemide acutely decreases airway resistance in chronic bronchopulmonary dysplasia</TI>
<SO>Journal of Pediatrics</SO>
<YR>1983</YR>
<VL>103</VL>
<NO>4</NO>
<PG>624-9</PG>
<IDENTIFIERS MODIFIED="2016-03-28 15:17:43 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-28 15:17:43 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6620024"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McCann-1985" MODIFIED="2016-03-28 15:18:07 -0400" MODIFIED_BY="[Empty name]" NAME="McCann 1985" TYPE="JOURNAL_ARTICLE">
<AU>McCann EM, Lewis K, Deming DD, Donovan MJ, Brady JP</AU>
<TI>Controlled trial of furosemide therapy in infants with chronic lung disease</TI>
<SO>Journal of Pediatrics</SO>
<YR>1985</YR>
<VL>106</VL>
<NO>6</NO>
<PG>957-62</PG>
<IDENTIFIERS MODIFIED="2016-03-28 15:18:07 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-28 15:18:07 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3889258"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Niermeyer-1988" MODIFIED="2016-02-29 23:33:07 -0500" MODIFIED_BY="[Empty name]" NAME="Niermeyer 1988" TYPE="BOOK_SECTION">
<AU>Niermeyer S</AU>
<TI>Nutritional and metabolic problems in infants with bronchopulmonary dysplasia</TI>
<SO>Bronchopulmonary dysplasia</SO>
<YR>1988</YR>
<ED>Bancalari E, Stocker JT</ED>
<PB>Hemisphere Publishing Corporation</PB>
<CY>Washington</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Northway-1967" MODIFIED="2016-03-28 15:18:34 -0400" MODIFIED_BY="[Empty name]" NAME="Northway 1967" TYPE="JOURNAL_ARTICLE">
<AU>Northway WH Jr, Rosan RC, Porter DY</AU>
<TI>Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1967</YR>
<VL>276</VL>
<NO>7</NO>
<PG>357-68</PG>
<IDENTIFIERS MODIFIED="2016-03-28 15:18:33 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-28 15:18:33 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="5334613"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2013" MODIFIED="2017-01-22 13:51:16 -0500" MODIFIED_BY="[Empty name]" NAME="Schünemann 2013" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Guyatt G, Oxman A, editors; GRADE Working Group</AU>
<TI>GRADE handbook for grading quality of evidence and strength of recommendations</TI>
<SO>Available from www.guidelinedevelopment.org/handbook</SO>
<YR>updated October 2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Viswanathan-2015" MODIFIED="2017-01-24 11:43:14 -0500" MODIFIED_BY="[Empty name]" NAME="Viswanathan 2015" TYPE="JOURNAL_ARTICLE">
<AU>Viswanathan S, McNelis K, Super D, Einstadter D, Groh-Wargo S, Collin M</AU>
<TI>Standardized slow enteral feeding protocol and the incidence of necrotizing enterocolitis in extremely low birth weight infants</TI>
<SO>JPEN. Journal of Parenteral and Enteral Nutrition</SO>
<YR>2015</YR>
<VL>39</VL>
<NO>6</NO>
<PG>644-54</PG>
<IDENTIFIERS MODIFIED="2016-03-28 15:19:02 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-28 15:19:02 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25316681"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-01-24 11:29:36 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-01-24 11:29:36 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-01-24 11:29:36 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fewtrell-1997">
<CHAR_METHODS MODIFIED="2016-03-28 17:57:33 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-28 18:01:36 -0400" MODIFIED_BY="[Empty name]">
<P>60 preterm infants &lt; 1500 grams and &lt; 32 weeks, dependent on oxygen at more than 28 days of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-24 11:29:36 -0500" MODIFIED_BY="[Empty name]">
<P>Standard formula (24 kcal/oz) at 180 mL/kg/day compared to high nutrient-density formula (30 kcal/oz) at 145 mL/kg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-15 13:22:06 -0400" MODIFIED_BY="[Empty name]">
<P>Growth variables, respiratory outcomes. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-01-24 11:29:16 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-10-04 09:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-04 09:19:47 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fewtrell-1997">
<DESCRIPTION>
<P>Pre-determined randomisation sequence in block of 4 and 6.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-01-24 11:29:05 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-24 11:29:05 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fewtrell-1997">
<DESCRIPTION>
<P>Randomisation sequences maintained in opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-10-15 13:12:32 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-10-15 13:12:32 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fewtrell-1997">
<DESCRIPTION>
<P>Not feasible to mask the intervention. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-01-24 11:29:09 -0500" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-01-24 11:29:09 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fewtrell-1997">
<DESCRIPTION>
<P>Outcome measures done by a research nurse not blind to the dietary randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-03-24 06:24:30 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-24 06:24:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fewtrell-1997">
<DESCRIPTION>
<P>All subjects accounted for in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-01-24 11:29:12 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-24 11:29:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fewtrell-1997">
<DESCRIPTION>
<P>No published or registered protocol was found.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-01-24 11:29:16 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-24 11:29:16 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fewtrell-1997">
<DESCRIPTION>
<P>The lack on concealment may have had an impact on the intervention itself: the medical staff were apparently reluctant to increase daily fluids, so the high-volume group did not receive as much fluid as planned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-04-06 15:04:02 -0400" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Funding Source</NAME>
<DESCRIPTION>
<P>Funding by local agencies, foundations, government bodies or industry.</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-06 15:04:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fewtrell-1997">
<DESCRIPTION>
<P>Study was funded by industry (Ross Laboratories) who also created the formulae. No indication is given about other roles of the funding source. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-01-24 11:32:40 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-01-24 11:32:40 -0500" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-09-12 14:44:17 -0400" MODIFIED_BY="GDT">Fluid restricted compared to liberal fluids compared to placebo for treatment of preterm babies with chronic lung disease</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Fluid restricted compared to liberal fluids compared to placebo for treatment of preterm babies with chronic lung disease</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Participant or population: </B>treatment of preterm babies with chronic lung disease<BR/>
<B>Setting: </B>
<BR/>
<B>Intervention: </B>Fluid restricted compared to liberal fluids<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with fluid restricted compared to liberal fluids</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Duration of oxygen therapy</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean duration of oxygen therapy was 27.5 days</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>median 0.5 days higher<BR/>(0 to 0 )</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>60<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Duration of hospitalisation</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean duration of hospitalisation was 85 days</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>MD 3 Days higher<BR/>(7.64 lower to 13.64 higher)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>60<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Daily weight gain</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean daily weight gain was 14.8 g/kg/d</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>MD 0.5 g/kg/d higher<BR/>(1.22 lower to 2.22 higher)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>60<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Proportion with apnoea</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 1.35<BR/>(0.98 to 1.86)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>60<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>630 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>850 per 1000<BR/>(617 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>630 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>850 per 1000<BR/>(617 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Unmasked study</P>
<P>
<SUP>2</SUP> Wide confidence limits</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-01-24 11:46:34 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2017-01-24 11:46:34 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Fluid restricted compared to liberal fluids</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.641987459312643" CI_START="-7.641987459312643" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2016-03-30 10:43:36 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5805933582502192" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="27" UNITS="" WEIGHT="100.00000000000001" Z="0.5525182186222891">
<NAME>Duration of hospitalisation</NAME>
<GROUP_LABEL_1>Restricted Fluids</GROUP_LABEL_1>
<GROUP_LABEL_2>Liberal Fluids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours restricted fluids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours liberal fluids</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.641987459312643" CI_START="-7.641987459312643" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="88.0" MEAN_2="85.0" MODIFIED="2016-02-29 23:28:31 -0500" MODIFIED_BY="[Empty name]" ORDER="393" SD_1="22.0" SD_2="20.0" SE="5.429685210164719" STUDY_ID="STD-Fewtrell-1997" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.2225291223461943" CI_START="-1.222529122346194" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2016-03-30 10:43:36 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5694101494461907" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.5689204203033905">
<NAME>Daily weight gain</NAME>
<GROUP_LABEL_1>Restricted Fluids</GROUP_LABEL_1>
<GROUP_LABEL_2>Liberal Fluids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours restricted fluids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours liberal fluids</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.2225291223461943" CI_START="-1.222529122346194" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="15.3" MEAN_2="14.8" MODIFIED="2016-02-29 23:28:55 -0500" MODIFIED_BY="[Empty name]" ORDER="394" SD_1="3.9" SD_2="2.9" SE="0.8788575381656417" STUDY_ID="STD-Fewtrell-1997" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.4382714244147059" CI_START="-5.609867042681849E-4" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.21885521885521886" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.35825684470898583" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.6598430926743568" METHOD="MH" MODIFIED="2017-01-24 11:46:34 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.05058863012375893" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="1.9549528973536368">
<NAME>Proportion with apnoea</NAME>
<GROUP_LABEL_1>Restricted Fluids</GROUP_LABEL_1>
<GROUP_LABEL_2>Liberal Fluids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours restricted fluids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours liberal fluids</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4382714244147059" CI_START="-5.609867042681849E-4" EFFECT_SIZE="0.21885521885521886" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-29 23:28:14 -0500" MODIFIED_BY="[Empty name]" ORDER="395" O_E="0.0" SE="0.11194910074379635" STUDY_ID="STD-Fewtrell-1997" TOTAL_1="33" TOTAL_2="27" VAR="0.012532601157344664" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-02-05 23:46:05 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-02-05 23:46:05 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAMlCAYAAABZ0nUeAABNnUlEQVR42u2dfYRVXd/Hb5IkSSQZ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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-01-22 13:52:35 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-01-22 13:52:35 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-03-15 08:36:42 -0400" MODIFIED_BY="[Empty name]">Standard search methodology</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-22 13:52:35 -0500" MODIFIED_BY="[Empty name]">
<P>Cochrane Library: (infant or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW)</P>
<P>PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or infan* or neonat*) AND (randomised controlled trial [pt] OR controlled clinical trial [pt] OR Clinical Trial[ptyp] OR randomised [tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh]))</P>
<P>Embase: (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW or Newborn or infan* or neonat*) AND (human not animal) AND (randomised controlled trial or controlled clinical trial or randomised or placebo or clinical trials as topic or randomly or trial or clinical trial)</P>
<P>CINAHL: (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or Newborn or infan* or neonat*) AND (randomised controlled trial OR controlled clinical trial OR randomised OR placebo OR clinical trials as topic OR randomly OR trial OR PT clinical trial)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;25 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;221 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;221 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;221 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;196 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;17 full-text articles excluded, as they did not compare different fluid intake volumes&lt;/p&gt;&lt;p&gt;7 full-text articles excluded as the studied infants in the first few days of life. &lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>